This protocol paper describes a three-year randomized controlled trial to be conducted in Kampala, Uganda.
Trials · 6 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This protocol paper describes a three-year randomized controlled trial to be conducted in Kampala, Uganda.
This protocol paper describes a three-year randomized controlled trial to be conducted in Kampala, Uganda. Arm 1 uses externally assigned subgoals adapted to baseline adherence; Arm 2 allows participants to set their own interim goals; and Arm 3 requires a uniformly fixed 90% adherence target. All groups receive weekly motivational messages. Adherence will be tracked continuously via Wisepill electronic devices over a 12-month intervention period and for 12 months post-intervention. Viral loads will be measured annually, and surveys conducted every six months. Secondary outcomes include treatment interruptions exceeding 48 hours, viral suppression at ≤200 copies/mL, and retention in care. This is a protocol paper; no trial results are reported.